"Recruitment for the dosimetry phase of @Clarity_Pharma&#39;s Cu-64/Cu-67 SAR-bisPSMA theranostic #ProstateCancer trial #SECuRE completed. #ReadNow details on UroToday &gt; https://t.co/5aIoFxoBK5 #PressRelease @DrNordquist"

64/67Cu SAR-bisPSMA theranostic - Clarity Pharma

Nov 12, 2021